Skip to main content

Table 3 Results of the generalized regression model

From: Determinants of orphan drugs prices in France: a regression analysis

Parameter p-value for type 3 statistics Estimate SE Wald 95% Confidence Limits p-value
Intercept   6.7811 0.8734 5.0693 8.4929 <.0001
Prevalence 0.1073 0.1632 0.1016 −0.0360 0.3624 0.1084
Age
 Adults 0.2753 −0.1691 0.3603 −0.8754 0.5371 0.6388
 Adults, paediatric 0.0268 0.4307 −0.8173 0.8709 0.9503
 Elderly −0.8188 0.5580 −1.9124 0.2749 0.1423
 Paediatric 0.0000 0.0000 0.0000 0.0000 .
Alternative
 No 0.0006 1.1042 0.3062 0.5041 1.7043 0.0003
 Non-pharmacological 1.7580 0.4483 0.8793 2.6368 <.0001
 One 0.1077 0.3216 −0.5227 0.7381 0.7377
 Several 0.0000 0.0000 0.0000 0.0000 .
Severity
 Not Severe 0.2602 0.2505 0.2196 −0.1799 0.6809 0.2540
 Severe 0.0000 0.0000 0.0000 0.0000 .
ATC
 A <.0001 2.4019 0.4458 1.5282 3.2755 <.0001
 B 0.6939 0.4266 −0.1422 1.5300 0.1038
 C 0.9708 0.4344 0.1194 1.8223 0.0254
 H 2.1675 0.4308 1.3232 3.0118 <.0001
 J −2.6030 0.7054 −3.9855 −1.2205 0.0002
 N 0.6858 0.5076 −0.3091 1.6807 0.1767
 V, R, G −1.6830 0.3856 −2.4387 −0.9273 <.0001
 L 0.0000 0.0000 0.0000 0.0000 .
Line
 First 0.4234 0.2195 0.2738 −0.3171 0.7561 0.4227
 Subsequent 0.0000 0.0000 0.0000 0.0000 .
IAB
 I <.0001 1.2641 0.4322 0.4169 2.1113 0.0035
 II 1.2281 0.3514 0.5394 1.9168 0.0005
 III −0.1662 0.3763 −0.9037 0.5714 0.6588
 IV −0.5557 0.3711 −1.2830 0.1716 0.1343
 V 0.0000 0.0000 0.0000 0.0000 .
Study
 Other 0.6266 0.6525 0.7739 −0.8643 2.1693 0.3992
 Phase II 0.1203 0.3037 −0.4748 0.7155 0.6919
 Phase III 0.0000 0.0000 0.0000 0.0000 .
Comparator
 Active <.0001 1.5872 0.3192 0.9616 2.2128 <.0001
 No 0.4590 0.3231 −0.1743 1.0923 0.1555
 Placebo 0.0000 0.0000 0.0000 0.0000 .
Endpoint
 Hard 0.1481 −0.4280 0.2905 −0.9973 0.1413 0.1406
 Surrogate 0.0000 0.0000 0.0000 0.0000 .
Commercialisation date
 2002–2003 0.0071 −0.2061 0.5230 −1.2311 0.8188 0.6934
 2004–2005 −0.8557 0.5956 −2.0232 0.3117 0.1508
 2006–2007 0.2278 0.4836 −0.7201 1.1756 0.6377
 2008–2009 0.0529 0.4049 −0.7407 0.8466 0.8960
 2010–2011 −0.2592 0.5049 −1.2487 0.7304 0.6077
 2012–2013 0.9553 0.4206 0.1310 1.7797 0.0231
 2014–2015 0.0000 0.0000 0.0000 0.0000 .
Delay HTA/Commercialisation 0.0048 −0.0318 0.0107 −0.0527 −0.0108 0.0029
Dispersion   0.2105 0.0385 0.1471 0.3011  
  1. ATC class: A Alimentary tract and metabolism; B Blood and blood forming organs; C Cardiovascular system; G Genito-urinary system and sex hormones; H Systemic hormonal preparations, excluding sex hormones and insulins; J Antiinfectives for systemic use; L Antineoplastic and immunomodulating agents; N Nervous system; R Respiratory system; V Various